Orpyx Medical Technologies announced that it launched its Orpyx SI sensory insoles with remote patient monitoring for the prevention of diabetic foot ulcers (DFU) and neuropathy-related ulcers.
The Orpyx SI sensory insole system is designed to monitor pressure, temperature and movement to provide real-time audiovisual alerts and allow users to immediately take action to resolve high-pressure areas that could result in tissue breakdown.
Calgary, Alberta-based Orpyx’s device uses a cloud-based dashboard to give healthcare providers a way to monitor real-world data and identify trends as well, according to a news release.
Orpyx reported that in a randomized controlled trial comparing the Orpyx SI technology to standard of care, the Orpyx system reduced DFU recurrence by up to 86% in patients with diabetic peripheral neuropathy and previous DFU.
“It is our mission to eliminate preventable DFUs,” Orpyx CEO & co-inventor Dr. Breanne Everett said in the release. “Current treatments are not enough. One in four people suffering from diabetes will develop a foot ulcer, and after the ulcer has healed, 40% of those will recur within the first year. Once a person develops a DFU, the 5-year mortality rate is almost 50%–higher than leukemia, colon cancer, and breast cancer. In my clinical practice, I saw the physical and emotional toll DFUs had on our patients and their families. If we can prevent DFUs from recurring, we can greatly improve peoples’ lives while avoiding costs.”
“The development of the Orpyx SI Sensory Insole system was a true collaboration with our healthcare providers and patients,” added Orpyx VP of commercial operations JR Locey. “For the first time, we are able to offer sensory feedback through a simple user interface to provide real-time data. Previously, this type of accuracy was only available in a research setting, but now it can be used in the real world to help prevent DFUs.”
